Kim EJ, et al. - Researchers estimated the concordance rates between the treatment options determined by Watson for oncology (WFO), a cognitive computing system providing decision support, and those determined by a multidisciplinary team (MDT). They reviewed the medical charts of patients diagnosed with colorectal cancer who visited the MDT at a single tertiary medical center and identified 69 patients with colorectal cancer who met with the MDT. The concordance rate of 46.4% was noted between chemotherapy regimens for colorectal cancer determined by MDT vs WFO recommendations. The MDT and National Comprehensive Cancer Network (NCCN) guidelines displayed a concordance rate of 97.1% and the WFO and NCCN guidelines had a concordance rate of 88.4%, after including the ‘For consideration’ category from WFO. In patients with stage II, IIIC, or IV disease significantly lower concordance rates between WFO and MDT were noted. The colorectal cancer stage was identified to be the only statistically significant factor distinguishing between WFO and MDT. The usefulness of WFO could be increased via further modification and improvement of the WFO prioritizing algorithm used to recommend treatment.